Company Creative Antibiotics Sweden AB

Creative Antibiotics Sweden AB, formerly Innate Pharmaceuticals AB, is a Sweden-based company that is active within the biotechnology industry. Its main business activity comprises the development of anti-infective agents to treat infectious diseases caused by Gram-negative bacteria. The agents disarm the pathogenic capability of certain bacteria, without affecting normal bacterial flora. The Company's activity is based on the research within innate immunity, medical chemistry and microbiology. It focuses on three projects, which involve the development of agents against severe burns, diarrhea diseases and chlamydia infections. As of December 31, 2011, the Company's three largest shareholders were Forsakringsaktiebolaget, Avanza pension (10.95%), Tuja Invest AB (6.23%) and Ostersjostiftelsen (5.67%).